PMID- 23564563
OWN - NLM
STAT- MEDLINE
DCOM- 20140609
LR  - 20211021
IS  - 1573-6709 (Electronic)
IS  - 0033-2720 (Linking)
VI  - 84
IP  - 4
DP  - 2013 Dec
TI  - Measurement methods of BDNF levels in major depression: a qualitative systematic 
      review of clinical trials.
PG  - 485-97
LID - 10.1007/s11126-013-9261-7 [doi]
AB  - There is evidence that the brain-derived neurotrophic factor (BDNF) has 
      implications for the pathophysiology of major depressive disorders (MDD). 
      Measures of BDNF levels are highly dependent on the methodologies used and these 
      vary among different studies. Therefore, the aim of this study was to carry out a 
      descriptive analysis of the methodologies used to measure BDNF in clinical trials 
      (CT) in patients with the diagnosis of major depression. We conducted a 
      qualitative systematic review of CT that included samples of subjects diagnosed 
      with major depression and evaluated the BDNF levels as an outcome. The search was 
      performed on Pubmed, Scielo, Psychinfo and Lilacs. The selected articles were 
      analyzed according to the CONSORT Statement and their methods of BDNF collection 
      and analysis were described. Twenty-eight studies were included in the final 
      analysis. Of those, 6 trials (21.4%) involved non-pharmacological interventions 
      and only half had the MDD diagnosis based on structured interview. Trials used 
      different methods to evaluate BDNF levels: most of them verified serum BDNF 
      levels, 17 (60.7%) trials mentioned that measured BDNF levels in duplicate and 9 
      (32.1%) collected blood in fasting. A variety of methods for BDNF collection and 
      analysis was used in the different studies, making it difficult to compare 
      results. However, despite of the methodology, BDNF seems to increase after 
      treatment for major depression.
FAU - Teche, Stefania Pigatto
AU  - Teche SP
AD  - UFRGS, Porto Alegre, Brazil, stepigatto@gmail.com.
FAU - Nuernberg, Gabriela Lotin
AU  - Nuernberg GL
FAU - Sordi, Anne Orgler
AU  - Sordi AO
FAU - de Souza, Livia Hartmann
AU  - de Souza LH
FAU - Remy, Lysa
AU  - Remy L
FAU - Cereser, Keila Maria Mendes
AU  - Cereser KM
FAU - Rocha, Neusa Sica
AU  - Rocha NS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Psychiatr Q
JT  - The Psychiatric quarterly
JID - 0376465
RN  - 0 (Antidepressive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - Antidepressive Agents/therapeutic use
MH  - Biomarkers/analysis
MH  - Brain-Derived Neurotrophic Factor/*analysis/blood/metabolism
MH  - *Clinical Trials as Topic
MH  - Depressive Disorder, Major/blood/drug therapy/*metabolism
MH  - Humans
MH  - Qualitative Research
MH  - Reagent Kits, Diagnostic
MH  - Specimen Handling/methods
MH  - Treatment Outcome
EDAT- 2013/04/09 06:00
MHDA- 2014/06/10 06:00
CRDT- 2013/04/09 06:00
PHST- 2013/04/09 06:00 [entrez]
PHST- 2013/04/09 06:00 [pubmed]
PHST- 2014/06/10 06:00 [medline]
AID - 10.1007/s11126-013-9261-7 [doi]
PST - ppublish
SO  - Psychiatr Q. 2013 Dec;84(4):485-97. doi: 10.1007/s11126-013-9261-7.